Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model.
The antibacterial activity of cefpodoxime proxetil was studied in an in-vitro model simulating doses of 100, 200 and 400 mg. Strains of Klebsiella spp. Proteus mirabilis, Escherichia coli, Streptococcus pyogenes, and Haemophilus influenzae were effectively reduced by a dose of 200 mg. While for Esch. coli no dose-activity relationship was observed--the maximal effect was achieved with a simulated dose of 100 mg--Staphylococcus aureus could be reduced effectively only by a simulated dose of 400 mg. The lower doses showed stepwise lower activities. Apart from broad spectrum beta-lactamases like SHV 2 or TEM 5 the presence of plasmid coded beta-lactamases in Esch. coli and H. influenzae did not affect the antibacterial activity of cefpodoxime proxetil. The results show that cefpodoxime was more active against Gram-negative bacteria than amoxycillin, and comparable activity to intramuscular cefotiam in the in-vitro model.
Wiedemann
B
B
Pharmaceutical Microbiology, Bonn, FRG.
Jansen
A
A
D000658:Amoxicillin / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D015310:Cefotiam / Q000494:pharmacology; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D013045:Species Specificity; D013211:Staphylococcus aureus / Q000187:drug effects; D001618:beta-Lactamases / Q000494:pharmacology; D000097627:Cefpodoxime Proxetil
D000658:Amoxicillin; D015310:Cefotiam; D015296:Ceftizoxime; D001618:beta-Lactamases; D000097627:Cefpodoxime Proxetil